Sprycel tablets 20 mg for leukemia

General information on Japanese tablets Sprycel 20 mg for leukemia

Package details: 30 tablets

Manufacturer: Bristol-Myers Squibb K.K., Japan

Active ingredient: dasatinib hydrate (chemical formula C22H28ClN7O3S)

Medical effect: Sprycel tablets are effective for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. They inhibit SRC-family protein-tyrosine kinases. By this, Sprycel tablets selectively inhibit the action of the abnormal protein necessary for leukemia cell proliferation and prevent leukemia cell proliferation.

Contraindications and precautions: sprycel tablets cannot be used for the following categories of patients:

1. patients with a history of any adverse reactions with imatinib,
2. patients with a history of interstitial pneumonia.
3. patients with impaired hepatic function, abnormal electrocardiogram, heart disease,
4. patients with thorombotic inhibitor,
5. pregnant or breastfeeding women.

Dosage and administration of Japanese tablets Sprycel 20 mg from Japan for leukemia

For chronic myeloid leukemia: in chronic phase take 100 mg of active ingredient 1 time a day. The consulting doctor may adjust the dosage according to the symptoms up to 140 mg 1 time a day. In accelerated phase or blast phase take 70 mg of active ingredient 1 time a day. The consulting doctor may adjust the dosage according to the symptoms up to 90 mg at a time 2 times a day.

For recurrent/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: take 70 mg of active ingredient at a time 2 times a day. The consulting doctor may adjust the dosage according to the symptoms up to 90 mg at a time 2 times a day.

Do not take grapefruit juice since or any food or supplement containing St. John's Wort while taking this medicine.

How effective are Sprycel tablets 20 mg from Japan for leukemia?

Sprycel tablets contain 50 mg of dasatinib hydrate, a small-molecule substance that inhibits the growth-promoting activities of protein-tyrosine kinases. By this, Sprycel tablets stop abnormal protein production necessary for tumor cells and prevent leukemia cell proliferation.

Who should use Sprycel tablets from Japan for leukemia?

Sprycel tablets can be used for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia cells harboring BCR-ABL kinase domain point mutations. It is also effective for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy (Y. Fujii, M. Amano, T. Seriu. Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel tablets 20 mg, 50 mg), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Nihon Yakurigaku Zasshi. 2009 Sep, 134(3): 159-67. Article in Japanese).